April 27, 2016 News by Patricia Silva, PhD MedDay’s MD1003, a Biotin, Shows ‘Remarkable’ Efficacy in Treating Inactive but Progressive MS in Clinical Trials MedDay recently disclosed full study results from the MS-SPI and MS-ON Phase 2b/3 trials of its therapeutic candidate MD1003 in patients with multiple sclerosis (MS). Specifically, the trials included people with “not active” progressive MS and those with either relapsing or progressive MS and visual loss, respectively. Data, presented at the recent American…
April 26, 2016 News by Patricia Silva, PhD At-Home ‘Brain Training’ Program for MS Patients Reported to Improve Cognitive Skills by 29% Multiple sclerosis patients using a cognitive remediation computer training program, part of a controlled trial by researchers from NYU Langone Medical Center, had greater improvements in cognitive function than those who used a placebo-training program, according to a presentation at the recent American Academy of Neurology annual meeting in Vancouver, Canada. Problems in attention, memory,…
April 22, 2016 News by Patricia Silva, PhD Biogen and AbbVie Present New Data Showing Zinbryta, an RRMS Drug Candidate, Aids Cognition Without Immune Depletion New data presented by Biogen and AbbVie at the recent 68th annual meeting of the American Academy of Neurology (AAN) showed that Zinbryta (daclizumab high-yield process) improved cognitive outcome measures in patients with relapsing forms of multiple sclerosis (RMS). Additional results — from post-hoc analyses of clinical trials — also offer a better…
April 20, 2016 News by admin Biogen Releases New Data Showing Effectiveness of Tecfidera in Newly Diagnosed MS Patients at AAN 2016 Biogen reported new data describing the effectiveness of Tecfidera (dimethyl fumarate) in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients in a recent presentation at the 68th annual meeting of the American Academy of Neurology (AAN). The conference, taking place in Vancouver, Canada, runs through April 21. Tecfidera is an…
April 20, 2016 News by Margarida Azevedo, MSc Sanofi Genzyme Presenting New Data on Lemtrada’s Beneficial Effects, Drawn from RRMS Extension Study, at AAN 2016 Sanofi Genzyme is presenting promising data regarding brain volume and retinal nerve fibers in multiple sclerosis (MS) patients — drawn from an ongoing extension study into the disease-modifying drug alemtuzumab (Lemtrada) — at the 2016 American Academy of Neurology (AAN) Annual Meeting taking place in Vancouver, Canada, through April…
April 19, 2016 News by Margarida Azevedo, MSc Promising Phase 1 Trial Results of Stem Cell Therapy in Progressive MS Patients Being Presented at AAN Meeting Potentially groundbreaking research by the Tisch Multiple Sclerosis Research Center of New York (MSRCNY) will be presented on April 19 at the 68th American Academy of Neurology (AAN) Annual Meeting taking place in Vancouver, Canada. Dr. Saud A. Sadiq, director and chief research scientist at the Tisch center, will present results of a…
April 18, 2016 News by Patricia Silva, PhD Sanofi Genzyme Presenting New Data on Its Approved and Investigational Multiple Sclerosis Treatments at AAN Sanofi Genzyme will present new data on its approved multiple sclerosis (MS) treatments — Lemtrada (alemtuzumab) and Aubagio (teriflunomide) — at the 68th annual meeting of the American Academy of Neurology (AAN), taking place in Vancouver, Canada, through April 21, as well as data on investigational therapies in its pipeline. In total, the meeting…
